Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on December 10, 2020. The company is listed on The Nasdaq Capital Market. This report addresses a specific regulatory event regarding the company's listing status rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate governance and listing compliance event.
Material Changes
The material change reported is the resolution of a prior listing deficiency. On December 10, 2020, the company received notification from Nasdaq that it regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This compliance was achieved because the closing bid price of the common stock was at least $1.00 per share for 10 consecutive business days. This action closes the matter previously disclosed in an 8-K filed on November 4, 2020.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading price of COCP to ensure it remains above the $1.00 minimum bid price threshold.
- Review the November 4, 2020, Form 8-K to understand the initial notification of non-compliance.
- Confirm the company's continued adherence to other Nasdaq listing requirements beyond the minimum bid price.